Cannabinoid hyperemesis syndrome

  title={Cannabinoid hyperemesis syndrome},
  author={Yaniv Chocron and J P Zuber and Julien Vaucher},
### What you need to know A 26 year old man attends the emergency department with a four week history of diffuse abdominal pain and nausea, along with vomiting every 30 minutes. Laboratory test results show a sodium level of 124 mmol/L (reference range 135-145) and a creatinine level of 348 µmol/L (62-106). During the last six years he has sought medical care several times for similar episodes, but no precise diagnosis was made, despite multiple investigations (including abdominal ultrasound… 
7 Citations
Cyclic vomiting syndrome: an important differential diagnosis of cannabinoid hyperemesis syndrome
The importance of cyclic vomiting syndrome (CVS) as a differential diagnosis, especially in patients presenting to emergency departments with episodes of vomiting, is emphasised.
Cannabinoid hyperemesis syndrome: implications for pregnancy
The article about cannabinoid hyperemesis syndrome as part of the Easily Missed? series is most welcome as “a way to help doctors . . . recognise conditions that are underdiagnosed or serious if not
Cannabinoid hyperemesis syndrome: caution with urine drug screens for marijuana
Chocron and colleagues provide a timely and important review on cannabinoid hyperemesis syndrome.1 One important point to expand on is the use (and pitfalls) of urine drug screens. Most available
Fetal and Neonatal Marijuana Exposure
A review of the literature for infants born prematurely provides an avenue for examining neuroplasticity through the study of those born too soon, so as to explain and compare this vulnerable period for any infant.
Cannabis use and cannabis use disorder
The epidemiology of cannabis use is reviewed, together with the epidemiology, mechanisms, diagnosis, prevention and treatment of Cannabis use disorder, and the risks associated with high-potency cannabis products are discussed.
Authors’ reply to Braillon and Bewley, Spiller and colleagues, and Wu
The aim was not to consider any issue related to legalisation or liberalisation of cannabis, but to emphasise the importance of recognising cannabinoid hyperemesis syndrome.
Übelkeit und Erbrechen als Symptome in der Notfallmedizin
  • D. Eis
  • Medicine
    Notfall + Rettungsmedizin
  • 2021
Nausea and vomiting (NV) are common symptoms in emergency medicine, accounting for 3–4% of presentations as chief complaint, and currently, Ondansetron is recommended as first line treatment in acute undifferentiated vomiting.


Hyperemesis and a high water bill.
A male patient aged 28 years was admitted with hyperemesis that did not cease in spite of different therapeutic approaches and had persisted for several days, and on the basis of these clinical findings, the diagnosis of cannabinoid hype Remesis syndrome was made.
Case of cannabinoid hyperemesis syndrome with long-term follow-up.
Physicians should have a high index of suspicion for this under-recognized condition, as excellent long-term prognosis of CHS can be achieved when abstinence is maintained.
Cannabinoid Hyperemesis Syndrome: Reports of Fatal Cases
These three cases demonstrate the importance of recognizing CHS as a potential cause or contributing factor to death in cannabinoid user.
Cannabinoid hyperemesis syndrome presentation to the emergency department: A two-year multicentre retrospective chart review in a major urban area.
This study suggests that Cannabinoid hyperemesis syndrome (CHS) may be an overlooked diagnosis for nausea and vomiting, a factor that can possibly contribute to unnecessary investigations and treatment in the ED.
The Cannabis Hyperemesis Syndrome Characterized by Persistent Nausea and Vomiting, Abdominal Pain, and Compulsive Bathing Associated with Chronic Marijuana Use: A Report of Eight Cases in the United States
Cannabis hyperemesis is characterized by otherwise unexplained recurrent nausea and vomiting, compulsive bathing, abdominal pain, and polydipsia associated with chronic cannabis use, which can occur in the United States as well as in Australia.
The Prevalence of Cannabinoid Hyperemesis Syndrome Among Regular Marijuana Smokers in an Urban Public Hospital
The prevalence of cannabinoid hyperemesis syndrome in a population of patients presenting to a socio‐economically and racially diverse urban Emergency Department of a public hospital is estimated to be about 2.75 million Americans, approximately 2.13–3.38 million of whom may suffer annually from a phenomenon similar to CHS.
Cannabinoid Hyperemesis Syndrome: A Case Report and Review of Pathophysiology
A patient with prior extensive work-up for nausea and vomiting and previous diagnosis of cyclic vomiting syndrome who presented with characteristic features of cannabinoid hyperemesis syndrome is described.